

HealthCare Global Enterprises Limited

Instruments	Amounts	Rating Action
	Rs. Crore	September 2016
Term loan facilities	323.80	[ICRA]BBB+ (Positive) / revised from [ICRA]BBB+ (Stable)
Long-term fund based facilities	55.00	[ICRA]BBB+ (Positive) / revised from [ICRA]BBB+ (Stable)
Long-term non-fund based facilities	12.00	[ICRA]BBB+ (Positive) / revised from [ICRA]BBB+ (Stable)
Long-term Interchangeable	(202.00)	[ICRA]BBB+ (Positive) / revised from [ICRA]BBB+ (Stable)
Proposed limits	133.41	[ICRA]BBB+ (Positive) / revised from [ICRA]BBB+ (Stable)

ICRA has reaffirmed the long term rating outstanding on the Rs.323.80 crore term loan facilities, the Rs.55.00 crore fund based facilities, the Rs.12.00 crore non-fund based facilities, the Rs.202.00 crore interchangeable facilities and the Rs.133.41 crore proposed limits of HealthCare Global Enterprises Limited (“HCG” / “the company”)¹ at [ICRA]BBB+ (pronounced ICRA triple B plus). The outlook on the long-term rating has been revised to Positive from Stable.

In arriving at the ratings, ICRA has taken a consolidated view of the HealthCare Global Group (comprising of HCG and its subsidiaries) considering the common management team and the presence of strong operational and financial linkages among the entities.

The revision in outlook takes into account the infusion of equity to the tune of Rs.252.3 crore into the company by way of fresh issue of shares through IPO during March 2016. Of the said amount, Rs.147.0 crore was utilized towards debt repayment. The total IPO size stood at Rs.649.6 crore. As on March 31, 2016, the company’s gearing and Total Debt / OPBDITA stood at 0.5x and 3.4x (down from 1.1x and 4.3x as on March 31, 2015). ICRA however notes that sizeable debt-funded capital expenditure plans towards geographical expansion is likely to maintain pressure on HCG’s debt protection metrics and cash flows going forward.

The rating continues to take into account HCG’s long standing presence, niche focus on cancer therapy, high brand equity of the hospital chain and strong reputation of the promoters in the field of oncology. High quality of infrastructure with advanced medical equipment and clinical research facilities has helped the company in attracting reputed consultants in turn aiding healthy patient inflow. With increasing penetration across India through its hub and spoke model, the company has strengthened its competitive position in the industry which is likely to support its operational parameters going forward. Cancer being a lifestyle disease, the treatment is spread over a longer duration with relatively higher realizations, which in turn is expected to support HCG’s revenue growth over the longer term.

The rating, however, remains constrained on account of aggressive capital expenditure plans to set up new units over the next three years. Further, commercialization of new units over the next three years is expected to strain the cash flows and profitability of the company while the capital-intensive nature of operations and relatively longer gestation periods of its new units are likely to maintain pressure on its accruals over the near-to-medium term.

The company’s ability to improve its operating performance, ease the pressure on profitability as well as coverage metrics and sustain its capital structure in the face of its future investment plans will remain key rating sensitivities going forward.

Company Profile

Established in 1989, HCG Group (“The Group”) is present primarily in the oncology field with largest cancer care network in South Asia. The Group has been promoted by Dr. B.S. Ajai Kumar, a practicing radiation and

¹ For complete rating scale and definitions, please refer ICRA’s website (www.icra.in) or other ICRA Rating Publications



medical oncologist with over 30 years of experience. Originally established with a single cancer care centre named Bangalore Institute of Oncology (BIO) at Bangalore by Dr. Kumar and four other oncologists, the Group has rapidly expanded its presence to Delhi, Ahmedabad, Chennai, Nasik, Ranchi, Cuttack, Hubli, Trichy and Vijayawada among others. The Group is currently present across the oncology value chain, offering services from prevention, screening, diagnosis and treatment to rehabilitation, supportive care and palliative care. The Group also has India's largest network of cancer care facilities with over 30,000 patients visiting the Group's hospitals every year.

Healthcare Global Enterprises Limited is the holding company of the Group. Acquired in the year 2000, as Curie Centre of Oncology Private Limited, Bangalore, the company was renamed HealthCare Global Enterprises Private Limited in 2005. Thereafter, in the following year, the company was converted to a public limited company. In 2010-11, Banashankari Medical and Oncology Research Centre Limited (BMORCL), HCG Group's oldest entity was merged with HCG forming a single large holding company. HCGEL presently has centres across Ahmedabad, Bangalore, Delhi, Chennai, Nasik, Ranchi, Cuttack, Hubli, Shimoga, Vijayawada and Trichy through subsidiaries and direct ownership.

Recent results (consolidated)

For FY2016, HCG reported net profit of Rs.5.4 crore on operating income of Rs.582.0 crore as against net profit of Rs.4.7 crore on operating income of Rs.519.6 crore during FY2015.

September 2016

For further details, please contact:

Analyst Contacts:

Mr. Subrata Ray (Tel. No. +91 22 6114 3408)
subrata@icraindia.com

Ms. Swathi Hebbar, (Tel. No. +91-80-4332 6404)
swathi.hebbar@icraindia.com

Ms. Mythri Macherla, (Tel. No. +91-80-4332 6407)
mythri.macherla@icraindia.com

Relationship Contacts:

Mr. Jayanta Chatterjee (Tel. No. +91-80-43326401)
jayantac@icraindia.com

© Copyright, 2016, ICRA Limited. All Rights Reserved
Contents may be used freely with due acknowledgement to ICRA

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.

**Registered Office****ICRA Limited**

1105, Kailash Building, 11th Floor, 26, Kasturba Gandhi Marg, New Delhi 110001
Tel: +91-11-23357940-50, Fax: +91-11-23357014

Corporate Office**Mr. Vivek Mathur**

Mobile: +91 9871221122

Email: vivek@icraindia.com

Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002
Ph: +91-124-4545310 (D), 4545300 / 4545800 (B) Fax; +91- 124-4050424

Mumbai**Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: shivakumar@icraindia.com

3rd Floor, Electric Mansion
Appasaheb Marathe Marg, Prabhadevi
Mumbai—400025,
Board : +91-22-61796300; Fax: +91-22-24331390

Kolkata**Mr. Jayanta Roy**

Mobile: +91 9903394664

Email: jayanta@icraindia.com

A-10 & 11, 3rd Floor, FMC Fortuna
234/3A, A.J.C. Bose Road
Kolkata—700020
Tel +91-33-22876617/8839 22800008/22831411,
Fax +91-33-22870728

Chennai**Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: jayantac@icraindia.com

5th Floor, Karumuttu Centre
634 Anna Salai, Nandanam
Chennai—600035
Tel: +91-44-45964300; Fax: +91-44 24343663

Bangalore**Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: jayantac@icraindia.com

'The Millenia'
Tower B, Unit No. 1004, 10th Floor, Level 2 12-14, 1 & 2,
Murphy Road, Bangalore 560 008
Tel: +91-80-43326400; Fax: +91-80-43326409

Ahmedabad**Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: shivakumar@icraindia.com

907 & 908 Sakar -II, Ellisbridge,
Ahmedabad- 380006
Tel: +91-79-26585049, 26585494, 26584924; Fax:
+91-79-25569231

Pune**Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: shivakumar@icraindia.com

5A, 5th Floor, Symphony, S.No. 210, CTS 3202, Range
Hills Road, Shivajinagar, Pune-411 020
Tel: + 91-20-25561194-25560196; Fax: +91-20-
25561231

Hyderabad**Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: jayantac@icraindia.com

4th Floor, Shobhan, 6-3-927/A&B. Somajiguda, Raj
Bhavan Road, Hyderabad—500083
Tel:- +91-40-40676500